253 related articles for article (PubMed ID: 14687447)
1. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
Kim IH; Park SK; Suh OK; Oh JM
Curr Med Res Opin; 2003; 19(8):753-9. PubMed ID: 14687447
[TBL] [Abstract][Full Text] [Related]
2. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
Kopf B; De Giorgi U; Vertogen B; Monti G; Molinari A; Turci D; Dazzi C; Leoni M; Tienghi A; Cariello A; Argnani M; Frassineti L; Scarpi E; Rosti G; Marangolo M
Bone Marrow Transplant; 2006 Sep; 38(6):407-12. PubMed ID: 16951690
[TBL] [Abstract][Full Text] [Related]
3. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
4. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
5. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial.
Schmitz N; Ljungman P; Cordonnier C; Kempf C; Linkesch W; Alegre A; Solano C; Simonsson B; Sonnen R; Diehl V; Fischer T; Caballero D; Littlewood T; Noppeney R; Schafhausen P; Jost L; Delabarre F; Marcus R
Bone Marrow Transplant; 2004 Dec; 34(11):955-62. PubMed ID: 15489865
[TBL] [Abstract][Full Text] [Related]
6. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
7. Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue.
Nolan L; Lorigan P; Chilton S; Newman J; Else R; Smith P; Linch D; Sweetenham JW; Johnson PW
Br J Haematol; 2007 Jun; 137(5):436-42. PubMed ID: 17433027
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
9. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)--results of a prospective randomised monocentre study.
Bönig H; Silbermann S; Weller S; Kirschke R; Körholz D; Janssen G; Göbel U; Nürnberger W
Bone Marrow Transplant; 2001 Aug; 28(3):259-64. PubMed ID: 11535993
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma.
Ossenkoppele GJ; Jonkhoff AR; Huijgens PC; Nauta JJ; van der Hem KG; Dräger AM; Langenhuijsen MM
Bone Marrow Transplant; 1994 Jan; 13(1):37-41. PubMed ID: 7517255
[TBL] [Abstract][Full Text] [Related]
11. Effects of rhG-CSF (filgrastim) on the recovery of hematopoiesis after high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children: a report from the Children's Cancer and Leukemia Study Group of Japan.
Suzue T; Takaue Y; Watanabe A; Kawano Y; Watanabe T; Abe T; Kuroda Y; Matsushita T; Kikuta A; Iwai A
Exp Hematol; 1994 Nov; 22(12):1197-202. PubMed ID: 7523170
[TBL] [Abstract][Full Text] [Related]
12. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
Schmitz N; Dreger P; Zander AR; Ehninger G; Wandt H; Fauser AA; Kolb HJ; Zumsprekel A; Martin A; Hecht T
Bone Marrow Transplant; 1995 Feb; 15(2):261-6. PubMed ID: 7539668
[TBL] [Abstract][Full Text] [Related]
13. Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Hüttmann A; Schirsafi K; Seeber S; Bojko P
J Cancer Res Clin Oncol; 2005 Mar; 131(3):152-6. PubMed ID: 15583936
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
16. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
Fenk R; Hieronimus N; Steidl U; Bruns I; Graef T; Zohren F; Ruf L; Haas R; Kobbe G
Exp Hematol; 2006 Oct; 34(10):1296-302. PubMed ID: 16982322
[TBL] [Abstract][Full Text] [Related]
17. Delayed administration of filgrastim (G-CSF) following autologous peripheral blood stem cell transplantation (APBSCT) in pediatric patients does not change time to neutrophil engraftment and reduces use of G-CSF.
Pai V; Fernandez SA; Laudick M; Rosselet R; Termuhlen A
Pediatr Blood Cancer; 2010 May; 54(5):728-33. PubMed ID: 20063422
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of recombinant human granulocyte colony-stimulating factor in children undergoing bone marrow transplantation.
Dini G; Floris R; Pession A; Manfredini L; Dallorso S; Lanino E; Garaventa A; Miano M; Kotitsa Z; Rondelli R
Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():121-8. PubMed ID: 8932813
[TBL] [Abstract][Full Text] [Related]
19. Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial.
Faber E; Pytlík R; Slabý J; Zapletalová J; Kozák T; Raida L; Papajík T; Zikesová E; Maresová I; Hamouzová M; Indrák K; Trnený M
Eur J Haematol; 2006 Dec; 77(6):493-500. PubMed ID: 17042769
[TBL] [Abstract][Full Text] [Related]
20. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses.
Suh C; Kim HJ; Kim SH; Kim S; Lee SJ; Lee YS; Kim EK; Kim SB; Lee JS; Kim MW; Kim K; Yoon SS
Transfusion; 2004 Apr; 44(4):533-8. PubMed ID: 15043569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
